Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Cholangiocarcinoma × Drug Therapy × Clear all

Phase

Phase 2 5 Phase 1/2 2 Phase 3 1 Phase 2/3 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 5 Precursor Cell Lymphoblastic Leukemia-Lymphoma 3 Neoplasms 3 Small Cell Lung Carcinoma 2 Sarcoma 2 Rectal Neoplasms 2 Ovarian Neoplasms 2 Esophageal Squamous Cell Carcinoma 2 Colorectal Neoplasms 2 Carcinoma, Hepatocellular 2 Breast Neoplasms 2 Uterine Cervical Neoplasms 1 Sarcoma, Ewing 1 SCLC 1 Retinoblastoma 1 Pancreatic Neoplasms 1 Osteosarcoma 1 Oligometastatic Disease 1 Neoplasms, Germ Cell and Embryonal 1 Nasopharyngeal Carcinoma 1 NSCLC 1 Mouth Neoplasms 1 Melanoma 1 Lymphoma, Follicular 1 Lymphoma 1 Lung Neoplasms 1 Locally Advanced Resectable Rectal Cancer 1 Glioblastoma 1 Gestational Trophoblastic Disease 1 Gastrointestinal Neoplasms 1

Interventions

Gemcitabine 4 Cisplatin 4 pembrolizumab 2 Photochemotherapy 2 futibatinib 1 Taxes 1 Radiofrequency Ablation 1 Paclitaxel 1 Neoadjuvant Therapy 1 Lasers 1 Fulvestrant 1 Drug Therapy 1 Capecitabine 1 Albumin-Bound Paclitaxel 1 1-phenyl-3,3-dimethyltriazene 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02807181 2025-05-09

SIRCCA

Sirtex Medical

Phase 2/3 Terminated

89 enrolled 23 charts

Gastrointestinal

Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡